Tysabri and PML: Legal Considerations and Illinois Statute of Limitations

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Targeted Legal Inquiry

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical treatments and their associated risks. Within this legacy framework, audiences have been educated about the balance between therapeutic benefit and potential adverse effects, fostering an informed patient population. This broad educational heritage now provides a critical backdrop for more specialized inquiries, particularly as individuals seek to navigate the legal and medical complexities arising from specific pharmaceutical exposures. As we pivot from this general health context, a focused concern emerges regarding the use of Tysabri (natalizumab) and its established link to Progressive Multifocal Leukoencephalopathy (PML). While the general health discourse covers a wide spectrum of drug safety, the occupational and patient-centered reality demands a sharper lens. For those who have been prescribed Tysabri, the risk of PML represents a tangible exposure concern that transcends theoretical knowledge. This transition is not merely about understanding a disease mechanism, but about recognizing a concrete exposure scenario that may carry legal implications. In Illinois, the statute of limitations for claims related to such pharmaceutical exposure becomes a critical factor for affected individuals. Thus, the legacy of general health education now serves as a stepping stone toward a more targeted, practical inquiry into the specific risks and legal timelines associated with Tysabri and PML.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn’s disease in adults. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and three established risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, memory loss, and visual changes. These symptoms overlap with those reported in adverse-event databases for Tysabri, which include fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), gait disturbance (9,422 reports), memory impairment (7,895 reports), asthenia (7,852 reports), balance disorder (5,621 reports), hypoesthesia (5,343 reports), muscular weakness (4,535 reports), cognitive disorder (3,478 reports), and depression (3,091 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While many of these reports may reflect underlying disease activity, the overlap with PML symptoms underscores the diagnostic challenge.

Mechanism of PML and Risk Factors

Diagnosis of PML requires MRI imaging and cerebrospinal fluid analysis for JCV DNA, and early detection is critical because treatment options are limited to supportive care and immune reconstitution. The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. By blocking lymphocyte adhesion and migration across the blood-brain barrier, Tysabri reduces immune surveillance in the central nervous system. This allows latent JCV, which is present in a majority of the population, to reactivate and infect oligodendrocytes, leading to demyelination and the characteristic lesions of PML. The risk is highest in patients who are anti-JCV antibody positive, have received Tysabri for more than two years, or have a history of immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning emphasizes that these factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). From a risk perspective, the adequacy of warnings regarding Tysabri and PML is a central issue. The prescribing information includes a boxed warning, a restricted distribution program called TOUCH, and detailed risk-factor guidance (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, patients and healthcare providers must weigh whether these warnings were sufficiently communicated and understood before treatment began.

Illinois Statute of Limitations for Tysabri-Related Claims

For affected patients in Illinois, attorney-related considerations include the statute of limitations for filing a product liability or medical malpractice claim. In Illinois, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. For claims involving Tysabri and PML, the timeline between exposure and documented harm is critical. PML can develop months to years after starting Tysabri, and symptoms may initially be mistaken for multiple sclerosis relapse. The date of diagnosis—confirmed by MRI and JCV testing—typically marks the point when the injury is discoverable. Patients who developed PML after prolonged Tysabri use, especially beyond two years, may have a stronger basis for alleging that the manufacturer failed to adequately warn about the cumulative risk over time. Given the severity of PML and its often irreversible neurological damage, affected individuals in Illinois should consult with an attorney experienced in pharmaceutical litigation to assess their specific circumstances. The statute of limitations may begin running from the date of PML diagnosis or from when the patient reasonably should have connected the harm to Tysabri. Delays in diagnosis can complicate the legal timeline, and early legal advice is advisable to preserve potential claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Illinois?

In Illinois, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. For Tysabri-related PML, the clock typically starts from the date of PML diagnosis, as that is when the injury becomes discoverable. However, delays in diagnosis can affect the timeline, so consulting an attorney promptly is crucial.

What are the main risk factors for developing PML while on Tysabri?

The three established risk factors for PML in Tysabri patients are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are outlined in the prescribing information and boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.